Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantActivity from announced rounds
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
Structured data and AI agents for clinical development and pharmaceutical trial operations.
Develops novel therapeutics for glaucoma and retinal diseases
Crossbow Therapeutics develops antibody therapies for cancer.
Develops precision immunoregulatory medicines based on tissue Treg biology
Develops bispecific antibodies for targeted degradation of extracellular proteins.